Publications by authors named "P J Schwartz"
Background: Congenital long QT syndrome (LQTS) is characterized by delayed ventricular repolarization, predisposing to potentially lethal ventricular arrhythmias. The variability in disease severity among patients remains largely unexplored, underscoring the limitations of current risk stratification methods.
Objective: We aimed to evaluate the potential utility of electrocardiographic markers from the exercise stress test (EST) in identifying patients with high-risk LQTS.
Background: Patients in low- and middle-income countries (LMICs) are disproportionately affected by liver cancers but there is a lack of understanding of their postoperative outcomes. This study aimed to review the current status of research in LMICs regarding outcomes after oncologic hepatectomy and synthesize the data reported in the literature.
Methods: The PubMed, Scopus, Embase, Web of Science, and World Health Organization (WHO) Global Index Medicus databases were searched from database inception to May 26th, 2022.
Article Synopsis
- * AAs were the first symptom of IAS in 52% of patients, and nearly a quarter had multiple AAs documented.
- * The study found a moderate incidence of severe outcomes, including a yearly primary endpoint rate of 1.4%, with younger patients experiencing higher risks and other complications affecting some patients as well.
Article Synopsis
- - The study investigated the effectiveness of ixabepilone (IXA) combined with bevacizumab (BEV) in treating ovarian cancers resistant to paclitaxel, revealing that the combination therapy significantly improves overall response rates (ORR) and progression-free survival (PFS) compared to ixabepilone alone.
- - A phase 2 clinical trial randomly assigned 76 patients, showing that those receiving IXA + BEV had a much higher ORR (38.4% vs. 8.1%) and greater PFS (5.5 months vs. 2.2 months) and overall survival (OS) (10.3 months vs. 6.0 months) despite many participants requiring
TREATING RADIO-IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN 2024: About 5 to 10% of patients with differentiated thyroid cancer (DTC) have advanced tumors at presentation or recurrence, with invasive cervical disease and/or distant metastases that cannot be effectively treated by conventional treatment, i.e. thyroid surgery and radioactive iodine.
View Article and Find Full Text PDF